Abstracts tagged "Gout and pseudogout"

Abstract Number: 354 • 2019 ACR/ARP Annual Meeting
Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Sukhraj Singh¹, Anthony Ocon ¹, Mark Riley ², Jennifer Tchervenkov ¹ and Ruben Peredo-Wende ¹, ¹Albany Medical Center, Albany, NY, ²Albany Medical Center, Albany
Background/Purpose: The Opioid Epidemic has been declared a public health emergency since 2017. The use of opioids in the acute crystal induced arthritis (ACIA) population…
Abstract Number: 2218 • 2018 ACR/ARHP Annual Meeting
Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis
Jean Liew and Gregory Gardner, Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Medically complex individuals may have contraindications to standard therapies for acute arthritis secondary to gout or calcium pyrophosphate disease (CPPD). Observational studies have demonstrated…
Abstract Number: 1132 • 2017 ACR/ARHP Annual Meeting
Compensated Polarized Microscopy for Crystal Identification Shows High Reliability Among Multiple Observers
José Antonio Bernal¹, Mariano Andrés^2,3, Salvador López-Salguero⁴, Vega Jovaní⁵, Paloma Vela^3,6 and Eliseo Pascual⁷, ¹Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ²Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³Universidad Miguel Hernández, Elche, Spain, ⁴Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Reumatología, Hospital general universitario de Alicante, Alicante, Spain, ⁶Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ⁷Emeritus Professor, Universidad Miguel Hernández, Elche, Spain
Background/Purpose: The gold standard for crystal-related arthritis diagnosis remains synovial fluid analysis by a microscope fitted with compensated polarized filters as it has been shown…
Abstract Number: 2090 • 2017 ACR/ARHP Annual Meeting
Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with Veterans Affairs Medical Center
Julianna Desmarais¹ and Cong-Qiu Chu², ¹Department of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology, Oregon Health & Science University, Portland, OR
Background/Purpose: Anakinra is an IL-1 blocking medication used off label to relieve acute inflammation from gout and pseudogout. The efficacy and safety of this treatment…
Abstract Number: L11 • 2014 ACR/ARHP Annual Meeting
Raman Spectroscopy: Point of Service Diagnosis Is Sensitive and Specific-a Tool for Improving Accuracy and Reducing Future Hospital Admission
Nora Singer¹, Bolan Li², Yener Yeni³, Emma Barnboym⁴, Steven Lewis⁵, Daniel Oravec⁶, Donald Haggins⁷ and Ozan Akkus², ¹Rheumatology, MetroHealth Medical Center and CWRU, Cleveland, OH, ²Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, ³Section of Biomechanics, Bone and Joint Cetner, Henry Ford Hospital, Detroit, MI, ⁴Rheumatology, MetroHealth Medical Center, Cleveland, OH, ⁵Medicine, MetroHealth Medical Center, Cleveland, OH, ⁶Bone and Joint Center, Henry Ford Hospital, Detroit, MI, ⁷Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: The diagnosis of gout or pseudogout hinges upon identification of monosodium urate (MSU) crystals and calcium pyrophosphate (CPPD) crystals in synovial fluid (SF) aspirates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].